Wallop of Symptoms and Co-morbidities on COVID-19 Outcome
Heba H. Abo ElNaga1, Hesham A. AbdelHalim2, *, Mohamed Abdellatif1, Haroun BG1, Basem Elnagdy1, Taghreed Ashraf1, Bahaa ElNaggar1, Passant S. Eldin1, Ismail TA1, Beshoy Mosaad1, Tasbeeha Ismail1, Rasmy Boules1, Shawky Methuselah1, Paula Rafaat1
Identifiers and Pagination:Year: 2021
First Page: 46
Last Page: 51
Publisher ID: TORMJ-15-46
Article History:Received Date: 3/5/2021
Revision Received Date: 18/7/2021
Acceptance Date: 5/8/2021
Electronic publication date: 10/11/2021
Collection year: 2021
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Fever, cough, fatigue, and myalgia are usually the original clinical picture of the COVID-19 pandemic, which appears non-specific and not exclusive.
To illustrate the clinical picture pattern and assess the prevalence of underlying co-morbidities and their correlation with the severity of COVID-19 infected patients.
A cross-sectional online survey included 580 participants who were either suspected or confirmed with COVID-19 infection.
The severity of the disease significantly correlates with both age (p=.01) and the time lag of the diagnosis of COVID-19 (p=.03). Hypertension (p=.015) and diabetes mellitus (p<.01) were significantly associated with the duration of symptoms. A wide range of ages (21-60 years) seemed to be the only risk factor for the severity. When symptoms were tested, dyspnea appeared to be the most prevalent symptom, predicting a more severe disease (OR= .066, 95% CI: .022- .200), followed by diarrhea (OR= .285, 95% CI: .122-.663), then fever (OR= .339, 95% CI: .139-.824). During the examination of co-morbidities influences on the severity, the only major co-morbidity that predicted a more severe disease was IHD (OR= .218, 95% CI: .073- .648), p= .006.
Special consideration is required for patients with COVID-19 with an associated longer gap between symptoms and diagnosis and associated co-morbidities including hypertension, diabetes, and established chronic kidney disease (CKD), for which this study proved its profound influence on the severity of the illness and duration of symptoms.